Akèy › Limfom Difize Gwo Selil B › Nevada
Etid klinik pou Limfom Difize Gwo Selil B nan Nevada
3 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Nevada.
Vil nan Nevada
Tèks ofisyèl etid la (Anglè)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Comprehensive Cancer Centers of Nevada, Las Vegas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Comprehensive Cancer Centers of Nevada ( Site 0168), Las Vegas
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05139017A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- OptumCare Cancer Care ( Site 0121), Las Vegas
- Comprehensive Cancer Centers of Nevada ( Site 0113), Las Vegas
- Cancer Care Specialists ( Site 9582), Reno
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.